Boron-neutron capture therapy in relation to immunotherapy

Area of Science:

• Oncology
• Radiation Oncology
• Neurosurgery

Background:

• Effective tumor therapy relies on host-tumor interaction and tumor cell reduction without immunosuppression.
• Conventional treatments like chemotherapy, surgery, and radiotherapy have limitations regarding immunosuppression and preservation of nervous function.
• Boron-neutron capture therapy (BNCT) emerges as a precise, low-immunosuppressive method for CNS tumors.

Purpose of the Study:

• To evaluate the efficacy of Boron-Neutron Capture Therapy (BNCT) for central nervous system (CNS) tumors.
• To compare BNCT outcomes with conventional treatment modalities.
• To present initial clinical results and discuss the therapeutic capacity.

Main Methods:

• BNCT involves utilizing a boron-10 isotope and thermal neutron irradiation for targeted tumor cell destruction.
• Review of basic research principles underlying BNCT.
• Analysis of interim clinical data from patients with recurrent glioblastoma and other CNS tumors.

Main Results:

• BNCT demonstrated a significant survival extension for recurrent glioblastoma patients (21.9 +/- 7.2 months) compared to conventional treatments (6.7 +/- 0.6 months).
• Total survival in BNCT-treated recurrent glioblastoma patients reached 26.3 +/- 6.7 months.
• Three patients, including two with glioblastoma, treated by a surgeon with prior knowledge of the tumor topography, survived for 4, 5, and 6 years in good condition.

Conclusions:

• BNCT is a promising, minimally immunosuppressive therapeutic option for CNS tumors, particularly recurrent glioblastoma.
• The specialized knowledge of the operating surgeon can enhance BNCT outcomes.
• Increased reactor capacity and boron-10 production are expanding BNCT's accessibility for more patients.